NO2920022T3 - - Google Patents

Info

Publication number
NO2920022T3
NO2920022T3 NO13855153A NO13855153A NO2920022T3 NO 2920022 T3 NO2920022 T3 NO 2920022T3 NO 13855153 A NO13855153 A NO 13855153A NO 13855153 A NO13855153 A NO 13855153A NO 2920022 T3 NO2920022 T3 NO 2920022T3
Authority
NO
Norway
Application number
NO13855153A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2920022(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed filed Critical
Publication of NO2920022T3 publication Critical patent/NO2920022T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
NO13855153A 2012-02-14 2013-11-13 NO2920022T3 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same

Publications (1)

Publication Number Publication Date
NO2920022T3 true NO2920022T3 (xx) 2018-06-09

Family

ID=48983616

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13855153A NO2920022T3 (xx) 2012-02-14 2013-11-13

Country Status (22)

Country Link
EP (3) EP2822576B1 (xx)
JP (2) JP6242819B2 (xx)
KR (3) KR102310704B1 (xx)
CN (2) CN104427994A (xx)
AU (3) AU2013219935B2 (xx)
BR (1) BR122021004014B1 (xx)
CA (1) CA2870621C (xx)
CL (2) CL2014002183A1 (xx)
CO (1) CO7131365A2 (xx)
DK (2) DK3326642T3 (xx)
EA (2) EA028578B1 (xx)
ES (2) ES2855133T3 (xx)
HK (1) HK1205460A1 (xx)
HU (1) HUE053068T2 (xx)
IL (2) IL264959B (xx)
MX (3) MX362446B (xx)
MY (1) MY172539A (xx)
NO (1) NO2920022T3 (xx)
PE (1) PE20142290A1 (xx)
PL (1) PL3326642T3 (xx)
SG (1) SG11201404836QA (xx)
WO (1) WO2013121416A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP2822576B1 (en) * 2012-02-14 2018-01-10 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20180111974A1 (en) 2014-12-10 2018-04-26 Opko Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
EP3310347B1 (en) * 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
TW201808988A (zh) * 2016-07-11 2018-03-16 歐科生物製品有限公司 長效型凝血因子及其生產方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
JP7023925B2 (ja) 2017-03-08 2022-02-22 テイ・エス テック株式会社 乗物用シート
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
US8865868B2 (en) * 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
EP2822576B1 (en) 2012-02-14 2018-01-10 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
EA033788B1 (ru) * 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина

Also Published As

Publication number Publication date
AU2013219935A1 (en) 2014-09-25
CL2014002183A1 (es) 2015-01-09
IL282121B (en) 2022-06-01
JP2015508771A (ja) 2015-03-23
MX2014009910A (es) 2015-09-28
BR112014020198A2 (pt) 2018-05-15
EA201790960A3 (ru) 2018-01-31
DK2822576T3 (en) 2018-04-16
AU2013219935B2 (en) 2016-02-04
EP3326642A1 (en) 2018-05-30
IL282121A (en) 2021-05-31
CA2870621A1 (en) 2013-08-22
WO2013121416A1 (en) 2013-08-22
JP2018065815A (ja) 2018-04-26
SG11201404836QA (en) 2014-12-30
IL264959B (en) 2021-08-31
EP3326642B1 (en) 2020-11-25
KR102118729B1 (ko) 2020-06-05
KR20140134673A (ko) 2014-11-24
HK1205460A1 (en) 2015-12-18
EA028578B1 (ru) 2017-12-29
MX362446B (es) 2019-01-18
CN109535245A (zh) 2019-03-29
CA2870621C (en) 2022-08-09
CN104427994A (zh) 2015-03-18
PE20142290A1 (es) 2015-01-15
MX2022008807A (es) 2022-08-11
CL2017002233A1 (es) 2018-05-11
DK3326642T3 (da) 2021-02-22
HUE053068T2 (hu) 2021-06-28
EP2822576A4 (en) 2015-11-25
JP6242819B2 (ja) 2017-12-06
ES2855133T3 (es) 2021-09-23
AU2017219044A1 (en) 2017-09-14
BR122021004014B1 (pt) 2022-12-27
EA201790960A2 (ru) 2017-09-29
CO7131365A2 (es) 2014-12-01
JP6510002B2 (ja) 2019-05-08
MY172539A (en) 2019-11-30
KR20210125595A (ko) 2021-10-18
AU2016202829B2 (en) 2017-05-25
KR20200063274A (ko) 2020-06-04
EP3791890A1 (en) 2021-03-17
AU2016202829A1 (en) 2016-05-19
MX2019000708A (es) 2020-09-02
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
EP2822576A1 (en) 2015-01-14
EA201491519A1 (ru) 2014-12-30
KR102310704B1 (ko) 2021-10-08
ES2665319T3 (es) 2018-04-25
EP2822576B1 (en) 2018-01-10
AU2017219044B2 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
BR112014017614A2 (xx)
BR112014017592A2 (xx)
BR112014017625A2 (xx)
BR112014017659A2 (xx)
BR112014017646A2 (xx)
AR092201A1 (xx)
BR112014017607A2 (xx)
BR112013027865A2 (xx)
BR112014017609A2 (xx)
BR112014017780A2 (xx)
BR112014017644A2 (xx)
BR112014017647A2 (xx)
BR112014017588A2 (xx)
BR112014017618A2 (xx)
NO2920022T3 (xx)
BR112014013184A8 (xx)
BR112014017630A2 (xx)
BR112014017652A2 (xx)
BR112014017621A2 (xx)
BR112014017622A2 (xx)
BR112014017627A2 (xx)
BR112014017623A2 (xx)
BR112014018287A2 (xx)
BR112014017667A2 (xx)
BR112014018223A2 (xx)